Why not consider an endothelin receptor antagonist against SARS‐CoV‐2?
Authors:
- 1 August 2020
- journal article
- letter
- Published by Elsevier in Medical Hypotheses
- Vol. 141, 109792
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jawsOral Oncology, 2020
- First Case of 2019 Novel Coronavirus in the United StatesNew England Journal of Medicine, 2020
- Discovering drugs to treat coronavirus disease 2019 (COVID-19)Drug Discoveries & Therapeutics, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Follow-up chest radiographic findings in patients with MERS-CoV after recoveryIndian Journal of Radiology and Imaging, 2017
- Bosentan as Rescue Treatment in Refractory Hypoxemia and Pulmonary Hypertension in a Patient with ARDS and H7N9 Influenza Virus InfectionLung, 2014
- Hypertension artérielle pulmonaire liée à l’infection VIH : de la pression artérielle pulmonaire à l’interleukine-6Revue de Pneumologie Clinique, 2011
- Evaluation of the Effect of Bosentan Treatment on Proinflammatory Cytokine Serum Levels in Patients Affected by Systemic SclerosisInternational Journal of Immunopathology and Pharmacology, 2011
- Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cellsJournal of General Virology, 2010